CAMBRIDGE NUTRITIONAL SCIENCES PLC (CNSL) — Research Note

Executive summary

CNSL (formerly Omega Diagnostics) is a UK-listed specialist medical diagnostics micro-cap focused on food sensitivity testing (FoodPrint®, Food Detective®, CNSLab service) after divesting its CD4/COVID businesses in 2022. Over the past five years the company has restructured out of a diverse group into a single-product-line entity, but revenue has drifted from £9.8m (FY24) to £8.3m (FY25) to £7.0m (FY26) and it swung from a small adjusted EBITDA profit back to a £0.4m loss with a £3m goodwill impairment 2026-09-08 final results. The single most important valuation anchor is that management's own value-in-use calculation of the sole CGU came out at £3.3m — matching the current market cap almost exactly, which caps upside unless the business re-accelerates.

Fair value estimate

• Range: 1.5p – 3.0p per share → implied market cap £3.6m – £7.1m
• Mid-point: 2.25p / £5.4m mcap → ~61% upside vs 1.40p / £3.3m current
• Methodology: Sanity-triangulated (a) NAV / cash floor (net current assets £4m incl. £2.6m cash = 1.7p), (b) management's own value-in-use DCF at 14% discount rate (£3.3m = 1.4p), (c) mid-cycle 6–8x adj EBITDA at recovered £8–9m revenue and 10–15% margin (£5–8m mcap).
• Key assumptions: revenue stabilises around FY26 levels, IVDR completes on time in 2027 unlocking European share, no further goodwill/deferred-tax writedowns, cash burn contained under the reverse stress test (which permits a further 15% revenue fall before liquidity is exhausted).
• Current market cap of £3.3m is essentially the company's own recoverable-amount ceiling — the market is pricing this as a near-liquidation case.

Sector context

Confirmed sector: Health Care (specialty diagnostics / medical devices). CNSL's quality/growth profile is materially below typical listed health-care peers: sub-scale (£7m revenue), loss-making, single-product-line, and reliant on distributors. Listed peers with some overlap: EKF Diagnostics (EKF.L) — point-of-care diagnostics, but far larger and profitable; Genedrive (GDR.L) — small AIM diagnostic peer, similarly speculative; Novacyt (NCYT.L) — molecular diagnostics comparator. CNSL is materially smaller and lower-quality than any of these.

Investment thesis (3 bullets)

1. Trading below tangible book with cash cushion. Net equity of £5.7m and cash of £2.6m against a market cap of £3.3m means investors are getting the operating business at a negative implied value; company's reverse stress test says revenue could fall a further 15% and gross margin drop 15pp before cash runs out 2026-09-08 final results.
2. Structural cost base rebased. UK headcount down from 76 to 58 FTE, gross margin improved to 67.8% (from 65.3%), production yields lifted from 52% to 65%, and management explicitly flags operating leverage — "with higher productivity and lower cost base CNS's operational leverage positions us well to translate future sales growth into improved profitability" 2026-09-08 final results.
3. IVDR project as a 2027 catalyst. Ongoing IVDR regulatory project is on track for completion in 2027 with new manufacturing technology that should drive further margin and open EU markets where IVDR is now mandatory; India (+23% Stg / +35% local ccy) and UK direct-lab (+11% testing volumes) already growing double-digit 2026-09-08 final results.

Key risks (3 bullets)

1. Revenue trend is down, not up. Two consecutive years of revenue decline (-15% then -16%), Americas -33% and Africa/ME -24% in FY26, and management guides that macro-economic drag continues into FY27 with "few early indications that this will alleviate in the short term" 2026-09-08 final results.
2. Customer/geographic concentration. One customer accounts for 18.6% of revenue and £0.3m bad-debt provision was taken on an Americas distributor whose product is "taking longer to sell, affected by changing policy and tariffs" 2026-09-08 final results.
3. Cash burn on a shrinking base. Cash fell from £4.9m to £2.6m in FY26 (-£2.3m in one year); another year of similar burn leaves the balance sheet stressed and forces a dilutive raise at what is already a distressed share price. Share price -55% over 12m confirms market skepticism 2026-09 market data + final results.

Operating leverage

Gross margin is high (67.8%) and rose 250bp YoY on yield improvements, so the unit economics argue for real operating leverage on incremental revenue. Fixed-cost UK base is now ~58 FTE with total staff costs c.£4.3m and administrative overheads c.£4.1m — together about £8.4m of largely fixed cost, against £7m revenue. Segment adj EBITDA in the trading division was £355k on £7m sales; if revenue recovered 15–20% to £8.0–8.4m at 68% GM with roughly flat costs, incremental gross profit of £0.7–1.0m would drop straight to EBITDA — plausibly quadrupling H&N adjusted EBITDA. However, absolute scale is tiny: even a doubling of operating profit is £0.5–1m, not a life-changing number, and the leverage cuts both ways as we've seen in FY26 2026-09-08 final results; 2025-11-10 half-year.

Value-trap signals

• Revenue declining two years running with management guiding continued softness into FY27.
• Goodwill written down to zero in FY26 (£3m impairment) — historically a marker of structural issues.
• Deferred tax asset of £1.4m fully written down; management judged future taxable profits insufficient to recognise it.
• Share price -55% YoY, -24% in the last 30 days, testing 52-week low.
• Repeated missed/lowered guidance vs analyst-implied expectations (H1 FY26 flagged sales "not reached expectations"; auditor bandwidth caused results delay 2026-08-17 updated notice).
• Long history of restructurings, name changes and strategic pivots — CD4 divestment, Alva site sale, DHSC dispute, aborted Ely relocation — suggests recurring execution difficulty.
• Product/market is niche (delayed-response food IgG testing), which the mainstream medical community treats as scientifically contested; barrier to broader adoption.

Earnings vs. expectations

Across the disclosed period, CNSL has consistently disappointed. FY22 was dominated by the collapse of the DHSC COVID contract and impairment charges. FY23 saw production yield problems and a warning that revenue would fall into the £7.5–8.0m range vs prior guidance 2023-01-18 trading update. FY24 delivered a positive surprise vs the reset base (revenue up 30% to £9.8m). FY25 outturn came in below expectations on core revenue (£8.3m vs prior H1 guidance implying stability), rescued only by the £2.5m DHSC one-off. FY26 H1 was flagged as disappointing with the full-year outcome revenue -16%. Pattern: more misses than beats, with beats typically driven by one-offs (DHSC settlement, backlog clearance) rather than clean operating execution.

Conviction

Conviction: 2 (low).

• Anchors: (i) management's own value-in-use of £3.3m matches current market cap, giving an unambiguous internal reference, (ii) the balance sheet is clean and cash-covered short term, (iii) segment margin dynamics are consistently disclosed.
• Limits: (i) revenue trajectory is negative and management gives no clear stabilisation point, (ii) the business is at a scale where a single lost distributor or delayed IVDR milestone dominates the P&L — small numbers, wide error bars, (iii) the market cap is so small that liquidity/dilution risk itself materially affects fair value.

Driver scoring

overall_score: 95 — poor fit for the AI-receiver / operating-leverage strategy. Zero AI exposure, sub-scale, declining top line, and only a partial valuation cushion. The cheap valuation is real but the underlying business is not what this strategy is looking for; the £3m mcap makes even a "correct" call barely meaningful position-size-wise. Not investable for this thesis.